Literature DB >> 24367196

Targeting γ-secretase in breast cancer.

Jianxun Han1, Qiang Shen2.   

Abstract

γ-secretase complexes are multisubunit protease complexes that perform the intramembrane cleavage of more than 60 type-I transmembrane proteins, including Notch receptors. Since dysregulated Notch signaling has been implicated in the tumorigenesis and progression of breast cancer, small molecule γ-secretase inhibitors (GSIs) are being tested for their therapeutic potential in breast cancer treatment in several clinical trials. Here, the structure of γ-secretase complex and the development of GSIs are briefly reviewed, the roles of Notch and several other γ-secretase substrates in breast cancer are discussed, and the difference between γ-secretase inhibition and Notch inhibition, as well as the side effects associated with GSIs, are described. A better understanding of molecular mechanisms that affect the responsiveness of breast cancer to GSI might help to develop strategies to enhance the antitumor activity and, at the same time, alleviate the side effects of GSI.

Entities:  

Keywords:  GSI; Notch; breast cancer; γ-secretase

Year:  2012        PMID: 24367196      PMCID: PMC3846591          DOI: 10.2147/BCTT.S26437

Source DB:  PubMed          Journal:  Breast Cancer (Dove Med Press)        ISSN: 1179-1314


  83 in total

Review 1.  Understanding the dual nature of CD44 in breast cancer progression.

Authors:  Jeanne M V Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2011-10-04       Impact factor: 5.852

Review 2.  Gamma-secretase and the intramembrane proteolysis of Notch.

Authors:  Ellen Jorissen; Bart De Strooper
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

3.  Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.

Authors:  M Kondratyev; A Kreso; R M Hallett; A Girgis-Gabardo; M E Barcelon; D Ilieva; C Ware; P K Majumder; J A Hassell
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

4.  Biological and clinical implications of nicastrin expression in invasive breast cancer.

Authors:  Aleksandra Filipović; Julian Hendrik Gronau; Andrew R Green; Jayson Wang; Sabari Vallath; Dongmin Shao; Sabeena Rasul; Ian O Ellis; Ernesto Yagüe; Justin Sturge; R Charles Coombes
Journal:  Breast Cancer Res Treat       Date:  2010-03-12       Impact factor: 4.872

5.  Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors.

Authors:  D Seiffert; J D Bradley; C M Rominger; D H Rominger; F Yang; J E Meredith; Q Wang; A H Roach; L A Thompson; S M Spitz; J N Higaki; S R Prakash; A P Combs; R A Copeland; S P Arneric; P R Hartig; D W Robertson; B Cordell; A M Stern; R E Olson; R Zaczek
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

6.  The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.

Authors:  Jianxun Han; Ivy Ma; Michael J Hendzel; Joan Allalunis-Turner
Journal:  Breast Cancer Res       Date:  2009-08-06       Impact factor: 6.466

7.  Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment.

Authors:  Shadmehr Demehri; Ahu Turkoz; Raphael Kopan
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

Review 8.  Breast cancer stem cells: something out of notching?

Authors:  Hannah Harrison; Gillian Farnie; Keith R Brennan; Robert B Clarke
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

9.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Authors:  Leopoldo Luistro; Wei He; Melissa Smith; Kathryn Packman; Maria Vilenchik; Daisy Carvajal; John Roberts; James Cai; Windy Berkofsky-Fessler; Holly Hilton; Michael Linn; Alexander Flohr; Roland Jakob-Røtne; Helmut Jacobsen; Kelli Glenn; David Heimbrook; John F Boylan
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Authors:  Pedro J Real; Valeria Tosello; Teresa Palomero; Mireia Castillo; Eva Hernando; Elisa de Stanchina; Maria Luisa Sulis; Kelly Barnes; Catherine Sawai; Irene Homminga; Jules Meijerink; Iannis Aifantis; Giuseppe Basso; Carlos Cordon-Cardo; Walden Ai; Adolfo Ferrando
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

View more
  8 in total

1.  Pharmacological disruption of the Notch transcription factor complex.

Authors:  Rajwinder Lehal; Jelena Zaric; Michele Vigolo; Charlotte Urech; Viktoras Frismantas; Nadine Zangger; Linlin Cao; Adeline Berger; Irene Chicote; Sylvain Loubéry; Sung Hee Choi; Ute Koch; Stephen C Blacklow; Hector G Palmer; Beat Bornhauser; Marcos González-Gaitán; Yvan Arsenijevic; Vincent Zoete; Jon C Aster; Jean-Pierre Bourquin; Freddy Radtke
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

Review 2.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

3.  DAPT Attenuates Cadmium-Induced Toxicity in Mice by Inhibiting Inflammation and the Notch/HES-1 Signaling Axis.

Authors:  Jia-Ying Yang; Dan-Yang Shen; Jun Wang; Jing-Feng Dai; Xiao-Yan Qin; Yang Hu; Rongfeng Lan
Journal:  Front Pharmacol       Date:  2022-04-29       Impact factor: 5.988

4.  b-Annulated 1,4-dihydropyridines as Notch inhibitors.

Authors:  Jorge E Gómez-Galeno; Cecilia Hurtado; Jiongjia Cheng; Ceren Yardimci; Mark Mercola; John R Cashman
Journal:  Bioorg Med Chem Lett       Date:  2018-09-05       Impact factor: 2.823

5.  Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ.

Authors:  Cecilia Hurtado; Alena Safarova; Michael Smith; Raeeun Chung; Arne A N Bruyneel; Jorge Gomez-Galeno; Franz Oswald; Christopher J Larson; John R Cashman; Pilar Ruiz-Lozano; Philip Janiak; Teri Suzuki; Mark Mercola
Journal:  Sci Rep       Date:  2019-07-25       Impact factor: 4.379

Review 6.  Tumor microenvironment pathways: Cross regulation in breast cancer metastasis.

Authors:  Rama Rao Malla; P Kiran
Journal:  Genes Dis       Date:  2020-12-01

7.  γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression.

Authors:  Shun-Fu Chang; Wei-Hsun Yang; Chun-Yu Cheng; Sheng-Jie Luo; Ting-Chung Wang
Journal:  Int J Med Sci       Date:  2021-04-26       Impact factor: 3.738

8.  Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells.

Authors:  Dougba Noel Dago; Claudio Scafoglio; Antonio Rinaldi; Domenico Memoli; Giorgio Giurato; Giovanni Nassa; Maria Ravo; Francesca Rizzo; Roberta Tarallo; Alessandro Weisz
Journal:  BMC Genomics       Date:  2015-05-09       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.